Terminated PHASE3 INTERVENTIONAL 2-arm NCT01110382

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections

Sponsor: Janssen Research & Development, LLC

Conditions Abdomen, Acute Abdominal Abscess Abdominal Pain Abscess, Intra-Abdominal Appendicitis Ileus Infection Intestinal Perforation Peritonitis Rupture

Interventions Amoxicillin/clavulanate potassium Doripenem Doripenem placebo Meropenem Meropenem placebo

Updated 8 times since 2017 Last updated: Jul 2, 2014 Started: Dec 31, 2010 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Trial terminated early per business decision

Other terminated trials from Janssen Research & Development, LLC

More terminations from Janssen Research & Development, LLC

A PHASE3 clinical study on Abdomen, Acute and Abdominal Abscess, this trial is terminated or withdrawn. The trial is conducted by Janssen Research & Development, LLC and has accumulated 8 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bogotá, Colombia , Buenos Aires, Argentina , Cleveland, United States , Córdoba, Argentina , Floridablanca, Colombia , Kaunas, Lithuania , Loma Hermosa, Argentina , Paraná, Entre Ríos, Argentina , Passo Fundo, Brazil , Riga, Latvia and 9 more locations